Thallium imaging for brain tumors with results measured by a semiquantitative index and correlated with histopathology

Walter J. Slizofski, Lalitha Krishna, Christos D. Katsetos, Perry Black, Curtis Miyamoto, Steven J. Brown, John R Vender, Anita Chevres, Angabeen S. Khan, Jack McEwan, Simin Dadparvar

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background. The optimal management of patients with brain tumors requires knowledge of the tumor characteristics upon presentation and the discovery of recurrence after therapy. Thallium‐201 (Tl‐201) chloride has shown varying uptake in tumors, depending on their viability and the type and degree of malignancy. This study explores the diagnostic potential of thallium imaging in patients with brain tumors. Methods. Forty‐three TI‐201 single photon emission computed tomographic scintigrams were performed on 40 patients with intracranial neoplasms, nearly equally divided between patients with no prior treatment and patients who had prior treatment and were suspected to have recurrent tumor and/or radiation necrosis. A thallium tumor index was calculated as the ratio of counts for a region of interest drawn in the lesion area and its mirror image in normal brain tissue. A two‐tailed Student's t test was performed to compare the thallium index and histopathologic findings. Results. A value of 1.5 for the thallium tumor index allowed for the best correlation between the prediction of malignancy and the histopathologic results. In the pretreatment group, a thallium tumor index greater than 1.5 correlated with high grade malignancy, and less than 1.5 correlated with either a well differentiated astrocytoma or benign cyst. In the posttreatment group, a thallium tumor index greater than 1.5 correlated with recurrent and/or residual malignant tumor. Conclusions. For those patients undergoing initial evaluation, the thallium study can help in the differential diagnosis of an intracranial mass lesion and offers confirmation of results of biopsy. For those patients who already have received treatment, the study can be used to detect recurrent or residual tumor.

Original languageEnglish (US)
Pages (from-to)3190-3197
Number of pages8
JournalCancer
Volume74
Issue number12
DOIs
StatePublished - Jan 1 1994

Fingerprint

Thallium
Brain Neoplasms
Neoplasms
Residual Neoplasm
Astrocytoma
Therapeutics
Photons
Cysts
Chlorides
Differential Diagnosis
Necrosis
Radiation
Students
Biopsy
Recurrence

Keywords

  • SPECT
  • brain tumor
  • glioma
  • histopathology
  • radiation necrosis
  • radionuclide
  • thallium‐201

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Thallium imaging for brain tumors with results measured by a semiquantitative index and correlated with histopathology. / Slizofski, Walter J.; Krishna, Lalitha; Katsetos, Christos D.; Black, Perry; Miyamoto, Curtis; Brown, Steven J.; Vender, John R; Chevres, Anita; Khan, Angabeen S.; McEwan, Jack; Dadparvar, Simin.

In: Cancer, Vol. 74, No. 12, 01.01.1994, p. 3190-3197.

Research output: Contribution to journalArticle

Slizofski, WJ, Krishna, L, Katsetos, CD, Black, P, Miyamoto, C, Brown, SJ, Vender, JR, Chevres, A, Khan, AS, McEwan, J & Dadparvar, S 1994, 'Thallium imaging for brain tumors with results measured by a semiquantitative index and correlated with histopathology', Cancer, vol. 74, no. 12, pp. 3190-3197. https://doi.org/10.1002/1097-0142(19941215)74:12<3190::AID-CNCR2820741218>3.0.CO;2-#
Slizofski, Walter J. ; Krishna, Lalitha ; Katsetos, Christos D. ; Black, Perry ; Miyamoto, Curtis ; Brown, Steven J. ; Vender, John R ; Chevres, Anita ; Khan, Angabeen S. ; McEwan, Jack ; Dadparvar, Simin. / Thallium imaging for brain tumors with results measured by a semiquantitative index and correlated with histopathology. In: Cancer. 1994 ; Vol. 74, No. 12. pp. 3190-3197.
@article{066077b08ef04d57bead2b5e4d371c1d,
title = "Thallium imaging for brain tumors with results measured by a semiquantitative index and correlated with histopathology",
abstract = "Background. The optimal management of patients with brain tumors requires knowledge of the tumor characteristics upon presentation and the discovery of recurrence after therapy. Thallium‐201 (Tl‐201) chloride has shown varying uptake in tumors, depending on their viability and the type and degree of malignancy. This study explores the diagnostic potential of thallium imaging in patients with brain tumors. Methods. Forty‐three TI‐201 single photon emission computed tomographic scintigrams were performed on 40 patients with intracranial neoplasms, nearly equally divided between patients with no prior treatment and patients who had prior treatment and were suspected to have recurrent tumor and/or radiation necrosis. A thallium tumor index was calculated as the ratio of counts for a region of interest drawn in the lesion area and its mirror image in normal brain tissue. A two‐tailed Student's t test was performed to compare the thallium index and histopathologic findings. Results. A value of 1.5 for the thallium tumor index allowed for the best correlation between the prediction of malignancy and the histopathologic results. In the pretreatment group, a thallium tumor index greater than 1.5 correlated with high grade malignancy, and less than 1.5 correlated with either a well differentiated astrocytoma or benign cyst. In the posttreatment group, a thallium tumor index greater than 1.5 correlated with recurrent and/or residual malignant tumor. Conclusions. For those patients undergoing initial evaluation, the thallium study can help in the differential diagnosis of an intracranial mass lesion and offers confirmation of results of biopsy. For those patients who already have received treatment, the study can be used to detect recurrent or residual tumor.",
keywords = "SPECT, brain tumor, glioma, histopathology, radiation necrosis, radionuclide, thallium‐201",
author = "Slizofski, {Walter J.} and Lalitha Krishna and Katsetos, {Christos D.} and Perry Black and Curtis Miyamoto and Brown, {Steven J.} and Vender, {John R} and Anita Chevres and Khan, {Angabeen S.} and Jack McEwan and Simin Dadparvar",
year = "1994",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19941215)74:12<3190::AID-CNCR2820741218>3.0.CO;2-#",
language = "English (US)",
volume = "74",
pages = "3190--3197",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Thallium imaging for brain tumors with results measured by a semiquantitative index and correlated with histopathology

AU - Slizofski, Walter J.

AU - Krishna, Lalitha

AU - Katsetos, Christos D.

AU - Black, Perry

AU - Miyamoto, Curtis

AU - Brown, Steven J.

AU - Vender, John R

AU - Chevres, Anita

AU - Khan, Angabeen S.

AU - McEwan, Jack

AU - Dadparvar, Simin

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Background. The optimal management of patients with brain tumors requires knowledge of the tumor characteristics upon presentation and the discovery of recurrence after therapy. Thallium‐201 (Tl‐201) chloride has shown varying uptake in tumors, depending on their viability and the type and degree of malignancy. This study explores the diagnostic potential of thallium imaging in patients with brain tumors. Methods. Forty‐three TI‐201 single photon emission computed tomographic scintigrams were performed on 40 patients with intracranial neoplasms, nearly equally divided between patients with no prior treatment and patients who had prior treatment and were suspected to have recurrent tumor and/or radiation necrosis. A thallium tumor index was calculated as the ratio of counts for a region of interest drawn in the lesion area and its mirror image in normal brain tissue. A two‐tailed Student's t test was performed to compare the thallium index and histopathologic findings. Results. A value of 1.5 for the thallium tumor index allowed for the best correlation between the prediction of malignancy and the histopathologic results. In the pretreatment group, a thallium tumor index greater than 1.5 correlated with high grade malignancy, and less than 1.5 correlated with either a well differentiated astrocytoma or benign cyst. In the posttreatment group, a thallium tumor index greater than 1.5 correlated with recurrent and/or residual malignant tumor. Conclusions. For those patients undergoing initial evaluation, the thallium study can help in the differential diagnosis of an intracranial mass lesion and offers confirmation of results of biopsy. For those patients who already have received treatment, the study can be used to detect recurrent or residual tumor.

AB - Background. The optimal management of patients with brain tumors requires knowledge of the tumor characteristics upon presentation and the discovery of recurrence after therapy. Thallium‐201 (Tl‐201) chloride has shown varying uptake in tumors, depending on their viability and the type and degree of malignancy. This study explores the diagnostic potential of thallium imaging in patients with brain tumors. Methods. Forty‐three TI‐201 single photon emission computed tomographic scintigrams were performed on 40 patients with intracranial neoplasms, nearly equally divided between patients with no prior treatment and patients who had prior treatment and were suspected to have recurrent tumor and/or radiation necrosis. A thallium tumor index was calculated as the ratio of counts for a region of interest drawn in the lesion area and its mirror image in normal brain tissue. A two‐tailed Student's t test was performed to compare the thallium index and histopathologic findings. Results. A value of 1.5 for the thallium tumor index allowed for the best correlation between the prediction of malignancy and the histopathologic results. In the pretreatment group, a thallium tumor index greater than 1.5 correlated with high grade malignancy, and less than 1.5 correlated with either a well differentiated astrocytoma or benign cyst. In the posttreatment group, a thallium tumor index greater than 1.5 correlated with recurrent and/or residual malignant tumor. Conclusions. For those patients undergoing initial evaluation, the thallium study can help in the differential diagnosis of an intracranial mass lesion and offers confirmation of results of biopsy. For those patients who already have received treatment, the study can be used to detect recurrent or residual tumor.

KW - SPECT

KW - brain tumor

KW - glioma

KW - histopathology

KW - radiation necrosis

KW - radionuclide

KW - thallium‐201

UR - http://www.scopus.com/inward/record.url?scp=0028114814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028114814&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19941215)74:12<3190::AID-CNCR2820741218>3.0.CO;2-#

DO - 10.1002/1097-0142(19941215)74:12<3190::AID-CNCR2820741218>3.0.CO;2-#

M3 - Article

C2 - 7982182

AN - SCOPUS:0028114814

VL - 74

SP - 3190

EP - 3197

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -